Myriad Genetics, Inc. (MYGN)
USD 7.39
(-0.14%)
USD 7.39
(-0.14%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2022 | 678.4 Million USD | -1.77% |
| 2021 | 690.6 Million USD | 23.99% |
| 2020 | 557 Million USD | -34.56% |
| 2019 | 851.1 Million USD | 0.0% |
| 2018 | 851.1 Million USD | 10.16% |
| 2017 | 772.6 Million USD | 0.16% |
| 2016 | 771.4 Million USD | 2.33% |
| 2015 | 753.8 Million USD | 4.25% |
| 2014 | 723.1 Million USD | -7.08% |
| 2013 | 778.21 Million USD | 26.92% |
| 2012 | 613.16 Million USD | 23.62% |
| 2011 | 496 Million USD | 23.36% |
| 2010 | 402.08 Million USD | 10.87% |
| 2009 | 362.64 Million USD | 11.06% |
| 2008 | 326.52 Million USD | -2.13% |
| 2007 | 333.62 Million USD | 112.33% |
| 2006 | 157.12 Million USD | 37.49% |
| 2005 | 114.27 Million USD | 38.68% |
| 2004 | 82.4 Million USD | 45.47% |
| 2003 | 56.64 Million USD | -11.93% |
| 2002 | 64.32 Million USD | 19.47% |
| 2001 | 53.83 Million USD | 19.21% |
| 2000 | 45.16 Million USD | 32.78% |
| 1999 | 34.01 Million USD | 34.44% |
| 1998 | 25.3 Million USD | 9.05% |
| 1997 | 23.2 Million USD | 52.63% |
| 1996 | 15.2 Million USD | 130.3% |
| 1995 | 6.6 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q2 | 183.5 Million USD | 1.27% |
| 2023 Q1 | 181.2 Million USD | 1.91% |
| 2023 Q3 | 191.9 Million USD | 4.58% |
| 2022 Q3 | 156.4 Million USD | -12.77% |
| 2022 Q2 | 179.3 Million USD | 8.73% |
| 2022 Q4 | 177.8 Million USD | 13.68% |
| 2022 Q1 | 164.9 Million USD | 2.55% |
| 2022 FY | 678.4 Million USD | -1.77% |
| 2021 Q3 | 167.3 Million USD | -11.67% |
| 2021 FY | 690.6 Million USD | 23.99% |
| 2021 Q2 | 189.4 Million USD | 9.42% |
| 2021 Q1 | 173.1 Million USD | 11.97% |
| 2021 Q4 | 160.8 Million USD | -3.89% |
| 2020 Q2 | 93.2 Million USD | -43.17% |
| 2020 FY | 557 Million USD | -34.56% |
| 2020 Q3 | 145.2 Million USD | 55.79% |
| 2020 Q4 | 154.6 Million USD | 6.47% |
| 2020 Q1 | 164 Million USD | -15.94% |
| 2019 Q3 | 186.3 Million USD | -13.51% |
| 2019 FY | 851.1 Million USD | 0.0% |
| 2019 Q1 | 216.6 Million USD | -0.09% |
| 2019 Q4 | 195.1 Million USD | 4.72% |
| 2019 Q2 | 215.4 Million USD | -0.55% |
| 2018 Q1 | 193.5 Million USD | -0.26% |
| 2018 FY | 851.1 Million USD | 10.16% |
| 2018 Q2 | 200.9 Million USD | 3.82% |
| 2018 Q3 | 202.3 Million USD | 0.7% |
| 2018 Q4 | 216.8 Million USD | 7.17% |
| 2017 Q1 | 196.9 Million USD | 0.2% |
| 2017 FY | 772.6 Million USD | 0.16% |
| 2017 Q4 | 194 Million USD | 2.0% |
| 2017 Q3 | 190.2 Million USD | -5.14% |
| 2017 Q2 | 200.5 Million USD | 1.83% |
| 2016 FY | 771.4 Million USD | 2.33% |
| 2016 Q2 | 186.5 Million USD | -2.1% |
| 2016 Q3 | 177.5 Million USD | -4.83% |
| 2016 Q4 | 196.5 Million USD | 10.7% |
| 2016 Q1 | 190.5 Million USD | -1.45% |
| 2015 FY | 753.8 Million USD | 4.25% |
| 2015 Q3 | 183.5 Million USD | -3.37% |
| 2015 Q4 | 193.3 Million USD | 5.34% |
| 2015 Q2 | 189.9 Million USD | 5.51% |
| 2015 Q1 | 179.98 Million USD | -2.39% |
| 2014 Q3 | 168.83 Million USD | -10.56% |
| 2014 Q4 | 184.39 Million USD | 9.21% |
| 2014 Q1 | 182.92 Million USD | -10.36% |
| 2014 FY | 723.1 Million USD | -7.08% |
| 2014 Q2 | 188.76 Million USD | 3.19% |
| 2013 Q2 | 174.11 Million USD | 11.28% |
| 2013 Q3 | 202.46 Million USD | 16.28% |
| 2013 Q4 | 204.06 Million USD | 0.79% |
| 2013 FY | 778.21 Million USD | 26.92% |
| 2013 Q1 | 156.47 Million USD | 4.92% |
| 2012 FY | 613.16 Million USD | 23.62% |
| 2012 Q1 | 129.77 Million USD | 5.67% |
| 2012 Q2 | 132.96 Million USD | 2.46% |
| 2012 Q3 | 133.43 Million USD | 0.35% |
| 2012 Q4 | 149.14 Million USD | 11.77% |
| 2011 Q4 | 122.81 Million USD | 11.19% |
| 2011 Q1 | 102.37 Million USD | 1.93% |
| 2011 FY | 496 Million USD | 23.36% |
| 2011 Q3 | 110.45 Million USD | 2.83% |
| 2011 Q2 | 107.41 Million USD | 4.92% |
| 2010 FY | 402.08 Million USD | 10.87% |
| 2010 Q4 | 100.44 Million USD | 9.34% |
| 2010 Q3 | 91.85 Million USD | -2.2% |
| 2010 Q2 | 93.92 Million USD | 3.41% |
| 2010 Q1 | 90.83 Million USD | -2.09% |
| 2009 FY | 362.64 Million USD | 11.06% |
| 2009 Q1 | 87.48 Million USD | 3.69% |
| 2009 Q3 | 85.12 Million USD | 5.07% |
| 2009 Q2 | 81.01 Million USD | -7.4% |
| 2009 Q4 | 92.76 Million USD | 8.98% |
| 2008 Q3 | 73.65 Million USD | -55.86% |
| 2008 FY | 326.52 Million USD | -2.13% |
| 2008 Q4 | 84.37 Million USD | 14.56% |
| 2008 Q2 | 166.85 Million USD | 170.15% |
| 2008 Q1 | 61.76 Million USD | 8.85% |
| 2007 FY | 333.62 Million USD | 112.33% |
| 2007 Q4 | 56.74 Million USD | 17.56% |
| 2007 Q3 | 48.26 Million USD | 6.13% |
| 2007 Q2 | 45.47 Million USD | 11.0% |
| 2007 Q1 | 40.97 Million USD | 10.33% |
| 2006 FY | 157.12 Million USD | 37.49% |
| 2006 Q2 | 32.02 Million USD | 7.43% |
| 2006 Q1 | 29.8 Million USD | 9.07% |
| 2006 Q3 | 33.54 Million USD | 4.74% |
| 2006 Q4 | 37.13 Million USD | 10.71% |
| 2005 Q4 | 27.33 Million USD | 8.82% |
| 2005 FY | 114.27 Million USD | 38.68% |
| 2005 Q3 | 25.11 Million USD | -3.76% |
| 2005 Q2 | 26.09 Million USD | 30.73% |
| 2005 Q1 | 19.96 Million USD | 1.64% |
| 2004 Q2 | 15.07 Million USD | 9.57% |
| 2004 Q1 | 13.75 Million USD | -2.77% |
| 2004 Q4 | 19.63 Million USD | 17.53% |
| 2004 Q3 | 16.71 Million USD | 10.87% |
| 2004 FY | 82.4 Million USD | 45.47% |
| 2003 Q2 | 15.7 Million USD | -2.39% |
| 2003 Q3 | 13.67 Million USD | -12.94% |
| 2003 Q4 | 14.14 Million USD | 3.48% |
| 2003 FY | 56.64 Million USD | -11.93% |
| 2003 Q1 | 16.08 Million USD | -5.47% |
| 2002 Q4 | 17.01 Million USD | 9.72% |
| 2002 FY | 64.32 Million USD | 19.47% |
| 2002 Q1 | 13.05 Million USD | -3.1% |
| 2002 Q2 | 14.11 Million USD | 8.07% |
| 2002 Q3 | 15.51 Million USD | 9.91% |
| 2001 Q4 | 13.47 Million USD | 2.16% |
| 2001 Q3 | 13.19 Million USD | 21.88% |
| 2001 Q1 | 11.56 Million USD | -3.23% |
| 2001 Q2 | 10.82 Million USD | -6.44% |
| 2001 FY | 53.83 Million USD | 19.21% |
| 2000 Q1 | 9.71 Million USD | 17.05% |
| 2000 Q2 | 9.15 Million USD | -5.74% |
| 2000 FY | 45.16 Million USD | 32.78% |
| 2000 Q3 | 10.81 Million USD | 18.15% |
| 2000 Q4 | 11.95 Million USD | 10.49% |
| 1999 Q2 | 6.9 Million USD | -2.82% |
| 1999 Q1 | 7.1 Million USD | 24.56% |
| 1999 Q4 | 8.3 Million USD | 20.29% |
| 1999 FY | 34.01 Million USD | 34.44% |
| 1999 Q3 | 6.9 Million USD | 0.0% |
| 1998 Q4 | 5.7 Million USD | 1.79% |
| 1998 FY | 25.3 Million USD | 9.05% |
| 1998 Q2 | 6.5 Million USD | 14.04% |
| 1998 Q3 | 5.6 Million USD | -13.85% |
| 1998 Q1 | 5.7 Million USD | 11.76% |
| 1997 Q4 | 5.1 Million USD | -13.56% |
| 1997 Q2 | 7.5 Million USD | 177.78% |
| 1997 Q3 | 5.9 Million USD | -21.33% |
| 1997 FY | 23.2 Million USD | 52.63% |
| 1997 Q1 | 2.7 Million USD | -3.57% |
| 1996 Q1 | 1.9 Million USD | 11.76% |
| 1996 FY | 15.2 Million USD | 130.3% |
| 1996 Q2 | 2 Million USD | 5.26% |
| 1996 Q3 | 2.2 Million USD | 10.0% |
| 1996 Q4 | 2.8 Million USD | 27.27% |
| 1995 Q4 | 1.7 Million USD | 70.0% |
| 1995 FY | 6.6 Million USD | 0.0% |
| 1995 Q3 | 1 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Biodesix, Inc. | 49.08 Million USD | -1282.036% |
| Castle Biosciences, Inc. | 219.78 Million USD | -208.661% |
| Exact Sciences Corporation | 2.49 Billion USD | 72.861% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 81.469% |
| 23andMe Holding Co. | 219.63 Million USD | -208.872% |
| NeoGenomics, Inc. | 591.64 Million USD | -14.664% |
| Neogen Corporation | 924.22 Million USD | 26.598% |
| Inotiv, Inc. | 572.42 Million USD | -18.513% |
| Psychemedics Corporation | 22.09 Million USD | -2969.961% |
| RadNet, Inc. | 1.61 Billion USD | 58.036% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -1381.708% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -26687.77% |
| Illumina, Inc. | 4.5 Billion USD | 84.938% |
| Aspira Women's Health Inc. | 9.15 Million USD | -7310.968% |
| Prenetics Global Limited | 21.74 Million USD | -3020.131% |
| iSpecimen Inc. | 9.92 Million USD | -6733.072% |
| OpGen, Inc. | 3.41 Million USD | -19746.006% |
| T2 Biosystems, Inc. | 7.19 Million USD | -9331.392% |
| Standard BioTools Inc. | 106.34 Million USD | -537.954% |
| Neuronetics, Inc. | 71.34 Million USD | -850.833% |
| Precipio, Inc. | 15.19 Million USD | -4364.039% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -21701.02% |
| Exagen Inc. | 52.54 Million USD | -1191.01% |
| Bionano Genomics, Inc. | 36.11 Million USD | -1778.392% |
| CareDx, Inc | 280.32 Million USD | -142.006% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 312.97 Million USD | -116.759% |
| Guardant Health, Inc. | 563.94 Million USD | -20.295% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -6843.132% |
| Natera, Inc. | 1.08 Billion USD | 37.334% |
| Fulgent Genetics, Inc. | 289.21 Million USD | -134.568% |
| Sera Prognostics, Inc. | 306 Thousand USD | -221599.346% |
| OPKO Health, Inc. | 863.49 Million USD | 21.436% |
| Personalis, Inc. | 73.48 Million USD | -823.232% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -2070.949% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -4975.017% |
| ICON Public Limited Company | 8.12 Billion USD | 91.646% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -1381.708% |
| MDxHealth SA | 70.19 Million USD | -866.478% |
| Prenetics Global Limited | 21.74 Million USD | -3020.131% |
| DarioHealth Corp. | 20.35 Million USD | -3233.333% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 64.027% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -75658.337% |
| Trinity Biotech plc | 56.83 Million USD | -1093.694% |
| Sotera Health Company | 1.04 Billion USD | 35.347% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -26687.77% |